Inactive Instrument

Inter Pharma Stock OTC Markets

IPTB.F

TH9474010005

Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Market Cap	3.03B 92.04M 79.2M 74.51M 68.07M 127M 8.69B 128M 881M 342M 4.46B 346M 338M 14.36B	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	3.15B 95.66M 82.32M 77.45M 70.75M 132M 9.03B 133M 915M 355M 4.63B 359M 351M 14.93B	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

14/08	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/05	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02/03	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/03	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
12/11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
12/11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/05/25	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
16/04/25	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
16/04/25	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
01/04/25	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
26/02/25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
26/02/25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI

17/08/22	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
10/08/22	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
10/08/22	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
10/08/22	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
10/08/22	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	01/02/2014
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	23/06/2023
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	14/06/2017
Sansanee Chaiyaroj BRD	Director/Board Member	64	01/08/2020
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	01/02/2014

Inter Pharma Stock OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation : Inter Pharma

Latest news : Inter Pharma

Press Releases : Inter Pharma

Managers and Directors : Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	92.04M
ELI LILLY AND COMPANY	-0.88%	-2.15%	+58.05%	+105.26%	1,024B
JOHNSON & JOHNSON	-1.15%	+2.68%	+54.25%	+74.19%	663B
ABBVIE INC.	-1.44%	+0.38%	+20.65%	+76.13%	453B
ROCHE HOLDING AG	-0.71%	+0.57%	+31.36%	+38.24%	352B
NOVARTIS AG	-2.42%	+3.00%	+24.08%	+43.25%	304B
ASTRAZENECA PLC	+0.97%	+1.50%	+1.44%	+12.18%	252B
AMGEN INC.	-1.55%	+1.11%	+54.15%	+75.59%	236B
NOVO NORDISK A/S	-0.31%	+2.24%	-13.83%	-55.80%	206B
GILEAD SCIENCES, INC.	-0.15%	+3.65%	+31.24%	+103.39%	187B
Average	-0.74%	+1.26%	+29.04%	+52.49%	408.71B
Weighted average by Cap.	-0.94%	+0.62%	+37.89%	+67.15%

	2024	2025
Net sales	1.91B 58.14M 50.03M 47.07M 43M 80.44M 5.49B 80.66M 556M 216M 2.82B 218M 214M 9.07B	2.21B 67.33M 57.93M 54.51M 49.79M 93.15M 6.36B 93.4M 644M 250M 3.26B 253M 247M 10.51B
Net income	37.28M 1.13M 975K 918K 838K 1.57M 107M 1.57M 10.84M 4.21M 54.91M 4.26M 4.16M 177M	122M 3.72M 3.2M 3.01M 2.75M 5.15M 351M 5.16M 35.6M 13.82M 180M 13.97M 13.67M 581M
Net Debt	209M 6.35M 5.47M 5.14M 4.7M 8.79M 600M 8.81M 60.78M 23.58M 308M 23.86M 23.33M 991M	119M 3.63M 3.12M 2.94M 2.68M 5.02M 342M 5.03M 34.7M 13.47M 176M 13.62M 13.32M 566M